CBDepot

As a pioneer in the production of high-quality cannabinoid ingredients, CBDepot has been a leader in helping to establish legal and quality standards for cannabinoid ingredients with roots dating to 2014. The company has achieved the formulation of cannabidiol derivatives that have a fast-growing presence in sectors including food, cosmetics, pharmaceuticals, and other health products.

“We started as a privately owned and funded company in 2015 and since then we operate solely on the private funds of the owners and we do not enjoy public funds as many of our competitors do,” says Mr. Boris Baňas, the Co-founder and Chief Sales Officer at CBDepot. “Our range is from true full-spectrum extracts with CBD and THC in the 20:1 ratio, which is intrinsic to industrial hemp, to broad spectrum distillates to highly purified isolated form with their synthetic equivalent.”

The production process of high-quality cannabinoid ingredients employed by CBDepot is either isolation by Class III solvents from distilled alcohol extract of GACP-certified Cannabis sativa L. or chemical synthesis.

As a result, clients can achieve various benefits. First, the novel food/new dietary ingredient status prevents food business operators from lawfully introducing CBD into foodstuffs. Second, cannabinoids are not soluble in water by definition.

“Several technological tricks exist to help CBD become somehow dispersed in the water matrix, but I have not seen any solution which actually tasted well, had stability, and did not contain nano particles at the same time. The use of engineered nanomaterials is also highly regulated in the EU and requires a pre-authorization,” states Mr. Baňas. “Most of the soda drinks contain preservatives and are infused with CO2 which render the pH acidic. Acidity and presence of water triggers conversion of CBD into THC.”

CBDepot has invested in industry-standard in-vitro safety studies for cosmetic and food use: eye irritation, eye phototoxicity, skin irritation, skin sensitization DPRA, skin sensitization LuSens, Bacterial Reverse Mutation Test (OECD 471), In vitro Mammalian Cell Micronucleus Test (OECD 487). On top of that, we have also performed in-vivo Sub-chronic toxicity (OECD 408), Genotoxicity (OECD 489) and ADME (OECD 417).

CBDepot’s commitment to Novel Food compliance began in early 2016, shortly after our shareholder Cannabis Pharma launched the CBDex brand. CBDepot’s EU application NF 2019/1371 was the first-ever CBD-specific dossier to have reached validation on March 27th, 2020. The NF2019/1371 covers synthesized Cannabidiol. In early January 2021, CBDepot filed two Regulated Product applications with the UK FSA to grant access for its two grades of Cannabidiol to the most significant legal CBD food supplement market worldwide. On February 15th, 2022, the European Commission (EC) declared CBDepot’s Novel Food application NF 2021/2283 for isolated Cannabidiol as valid. This sets the number of CBDepot’s valid Novel Food applications with EC and FSA to four.